Experimental drug offers hope for Tough-to-Treat amyloidosis
NCT ID NCT05145816
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a drug called belantamab mafodotin in people with a rare blood disease called AL amyloidosis that has come back or not responded to other treatments. The goal is to find the safest and most effective dose. The study has two parts: first, different doses are tested for safety, then the best dose is studied further in more people.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AL AMYLOIDOSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Huntsman Cancer Institute, University of Utah
NOT_YET_RECRUITINGSalt Lake City, Utah, 84112, United States
-
UT Southwestern Medical Center
RECRUITINGDallas, Texas, 75390, United States
-
Vanderbilt Ingram Cancer Center
NOT_YET_RECRUITINGNashville, Tennessee, 37232, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A hidden warning in your wrist? surgery may reveal heart risk
- Can a daily pill keep a rare heart disease in check for the long haul?
- Can a Dual-Targeting antibody stop amyloid buildup in its tracks?
- Can a radioactive peptide spot hidden amyloid in the heart?
- Real-world data on multiple myeloma immunotherapies could reshape monitoring and improve survival
- Heart drug acoramidis tested for Long-Term cardiac repair in rare amyloidosis